Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib as Sequential Therapy in Unresectable Stage III NSCLC
NCT03743129Phase 2Completed
- Start
- Apr 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in non-small cell lung cancer (NSCLC). Started Apr 2019; status: completed.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03743129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03743129.